Background: Pregabalin is a first-line agent for neuropathic pain treatment whose abuse liability remains controversial. Surprisingly, studies exploring the reinforcing properties of pregabalin in operant mouse models are missing. Methods: We evaluated the acquisition of operant pregabalin selfadministration in mice exposed to a partial sciatic nerve ligation (PSNL) or a sham operation. After surgery, mice were trained in operant boxes to intravenously self-administer pregabalin at 1.5 or 3 mg/kg/inf or saline during 10 days. Thermal and mechanical sensitivity were assessed before and after self-medication, and depressive-like behaviour was evaluated after discontinuation of the treatment. Results: Partial sciatic nerve ligation and sham-operated mice exposed to pregabalin at 3 mg/kg/inf showed higher active responding compared to mice exposed to saline. The differences in active responding were more robust in nerve-injured than in sham-operated mice. Selfmedication at either dose of pregabalin partially inhibited thermal hypersensitivity, whereas only self-medication at 3 mg/kg/inf reduced mechanical sensitivity. Finally, a depressive-like behaviour was revealed after saline treatment in nerve-injured mice, and this emotional manifestation was abolished after pregabalin treatment at the high dose. Conclusions: Pregabalin showed reinforcing effects both in PSNL and sham-operated mice and attenuated the nociceptive and emotional manifestations of neuropathic pain in mice self-administering this drug. Therefore, pregabalin self-administration was related to neuropathic pain relief, but also to reinforcing properties related to psychotropic drug effects. This study reveals the improvement in nociceptive and emotional manifestations of neuropathic pain after operant pregabalin self-medication in mice and suggests the reinforcing effects of this drug in an operant paradigm. Significance: This study shows that mice with a nerve injury selfadminister pregabalin at doses effective reducing nociceptive hypersensitivity and depressive-like behaviour associated with the neuropathic pain model. Interestingly, mice without neuropathy also develop operant self-administration behaviour, suggesting potential abuse liability of this first-line drug for neuropathic pain treatment.
Introduction
Pregabalin is an antiepileptic drug prescribed as firstline treatment for chronic neuropathic pain (Finnerup et al., 2015) mainly acting on the a2d-1 calcium channel subunit, which is critical for functional expression of voltage-gated calcium channels (Field et al., 2006; Patel and Dickenson, 2016) . Multiple preclinical studies have shown the efficacy of pregabalin alleviating hypernociception associated with neuropathic injuries (Field et al., 1999 (Field et al., , 2006 Nozaki-Taguchi et al., 2001; Kremer et al., 2016) . While some of these studies describe complete reversion of neuropathic hypersensitivity, it should be noted that the number of patients needed to treat for 50% pain relief (i.e. patients who need to be treated to obtain one with a 50% of pain relief) is estimated between 6.5 and 9.4 (Finnerup et al., 2015) . This discordance between clinical data and preclinical studies may be related to the measurement of evoked sensitivity in the current preclinical studies. While one of the most prevalent symptoms in chronic neuropathic syndromes is spontaneous pain (96% of the cases (Backonja and Stacey, 2004) ), studies estimating the efficacy of pregabalin alleviating spontaneous manifestations of neuropathic pain models in mice are lacking.
Different clinical studies (Papazisis and Tzachanis, 2014; Bossard et al., 2016; Schjerning et al., 2016; Evoy et al., 2017) and individual reports (Filipetto et al., 2010; Papazisis et al., 2013; Halaby et al., 2015) have pointed out the potential abuse liability of pregabalin, particularly when treating psychiatric disorders and in patients with concomitant abuse of other medications. Surprisingly, few studies have used animal models to estimate the ability of pregabalin to induce abuse or to alleviate spontaneous pain (Table 1) . A first study failed to show pregabalin-induced conditioned place preference (CPP) after oral treatment in rats (Andrews et al., 2001) , whereas a more recent study showed CPP after intraperitoneal administration to rats without pain (Rutten et al., 2011) . In the context of pain, pregabalin reduced conditioned place aversion in a rat model of carrageenan-induced inflammation, which seemed related to its capability to alleviate pain manifestations (Rutten et al., 2011) . Higher doses of pregabalin induced rewarding effects in carrageenantreated rats, although it could not be distinguished whether the reward was associated with pain relief or with psychotropic drug effects (Rutten et al., 2011) . These previous results showed the effects of pregabalin facilitating context-drug associative learning. However, the ability of pregabalin to induce drug-taking behaviour in the context of chronic neuropathic pain models or in the absence of pain has never been evaluated. Self-administration models in which animals are required to elicit an operant response to obtain a drug represent an approach with high face validity, useful to estimate drug efficacy alleviating spontaneous, nonevoked pain (Gutierrez et al., 2011; Bura et al., 2013) . At the same time, operant drug self-administration shows high predictive validity assessing the reinforcing properties of drugs in rodents and nonhuman primates which are related to its abuse liability potential (O'Connor et al., 2011) . The combination of both approaches could serve to estimate the ability of pregabalin to elicit an operant drug-taking behaviour selectively associated with relief of spontaneous pain-related manifestations or with reinforcing properties related to its psychoactive effects. Previous studies evaluating the efficacy of pregabalin in mouse models of neuropathic pain have revealed incomplete efficacy of the drug inhibiting other aspects of chronic neuropathic syndromes, including anxiety-like behaviour, cognitive impairment or decreased motivation for food (GalanArriero et al., 2014; La Porta et al., 2016) .
Here, we used an operant self-administration paradigm to evaluate the reinforcing effects of pregabalin in a mouse model of neuropathic pain. This paradigm mimics self-medication with painkillers in humans, in the sense that an effective analgesic drug will reinforce the response of taking the drug in individuals with pain. At the same time, pregabalin-induced reinforcement was measured in mice free of neuropathic injury. The maintenance of an operant behaviour for pregabalin in these mice would be indicative of abuse potential. In our experimental paradigm, sensitivity to mechanical and thermal stimuli was assessed before and after the drug self-administration period to confirm the antinociceptive activity of pregabalin, and emotional consequences of the self-treatment were estimated by measuring depressive-like behaviour at the end of the experimental sequence.
Methods

Animals
C57BL/6J male mice (Charles River, Domaine des Oncins, BP, 0109, L'Arbresle, France), weighing 22-24 g at the beginning of the experiments, were used. Mice were housed in a temperature (21 AE 1°C) and humidity-controlled (55 AE 10%) room, and handled during the dark phase of a 12-h light/dark reverse cycle (light off at 08:00 a.m., light on at 8:00 p.m.). Before starting the experimental procedure, mice were single-housed and handled/habituated during 7 days. Food and water were available ad libitum except during the training period for food-maintained operant behaviour, when mice were exposed to a restricted diet during 8 days. The experimental procedure (Fig. 1 ) and the animal husbandry were conducted according to standard ethical guidelines (European Community Guidelines on the Care and Use of Laboratory Animals 86/609/EEC) and were approved by the local ethical committee (Comit e Etico Experimental Animal, Instituto Municipal de Asistencia Sanitaria/Universitat Pompeu Fabra).
Drugs
Pregabalin (generously provided by Laboratorios Dr. Esteve, Barcelona, Spain) was dissolved in physiological sterile saline solution (0.9%) and selfadministered intravenously (i.v.) at 1.5 or 3 mg/kg/ infusion in an infusion volume of 23.5 ll per injection. These doses were selected on the basis of previous studies reporting behavioural effects of pregabalin in mice (Vartanian et al., 2006; Wang et al., 2015) . Higher pregabalin concentrations were avoided to prevent sedation or other possible nonspecific effects that could interfere with operant responding. Thiopental was dissolved in saline and administered through the implanted catheter at a dose of 10 mg/kg.
Drug self-administration procedure
Mice were first trained for operant food self-administration to facilitate drug self-administration to alleviate the spontaneous manifestations of the neuropathic pain model, as previously described Figure 1 Experimental procedure. Mice were food-restricted (days -9 to -2) and trained for 5 days to acquire an operant self-administration behaviour for food (-6 to -2). Afterwards, mice were subjected to a partial sciatic nerve ligation (PSNL) or sham surgery (day 0). Following catheter i.v. implantation on day 4, mice were trained again in the operant chambers on day 7 to acquire an operant behaviour maintained by i.v. infusions of pregabalin at 1.5 or 3 mg/kg or saline, during 10 days (from days 7 to 16). The thiopental test (i.v. injection of thiopental) served to check the patency of the catheter at the end (day 16). Mice were habituated to nociceptive tests the day before the PSNL/sham surgery. Nociceptive tests consisted on plantar and von Frey tests to measure heat and mechanical sensitivity, respectively. Nociception was evaluated before (days 0, 3, 6) and after the drug self-administration period (day 16). Depressive-like behaviour was assessed the day after the last self-administration session (day 17) using the tail suspension test. ( Bura et al., 2013) with some modifications. Briefly, mice were food-restricted for 3 days to reach 90% of their initial weight ( Fig. 1) . Then, mice were trained in operant chambers (model ENV-307A-CT, Med Associates Inc., Georgia, VT, USA) for 5 days (1-h session per day) to acquire an operant behaviour to obtain food pellets. A fixed ratio 1 schedule of reinforcement (FR1) was used during the whole training period, i.e., one nose-poke on the active hole resulted in the delivery of one reinforcer together with a stimulus light for 2 s (associated cue). Nosepoking on the inactive hole had no consequence. Each session started with a priming delivery of one reinforcer and a timeout period of 10 s after each reinforcer delivery, where no cues were presented and no reward was provided following active nosepokes. Food self-administration sessions lasted 1 h or until mice nose-poked 100 times on the active hole, whichever happened first. After completion of food training, mice underwent a partial sciatic nerve ligation (PSNL) or sham surgery, and 4 days later, an i.v. catheter was implanted to allow i.v. self-administration. After catheter implantation, mice started the drug self-administration sessions on day 7. The food reinforcer was substituted by drug/saline infusions in operant training sessions. Self-administration sessions were conducted during 10 consecutive days, and mice received pregabalin (1.5 or 3 mg/kg) or saline under FR1. Sessions lasted 1 h or until 60 active nose-pokes. Active and inactive nose-pokes were recorded after each session.
Partial sciatic nerve ligation
PSNL was performed at mid-thigh level to induce neuropathic pain, as previously described (Malmberg and Basbaum, 1998; Bura et al., 2008) . Briefly, mice were anaesthetized with isoflurane (induction, 5%; surgery, 2%), and the sciatic nerve was exposed at the level of the mid-thigh of the right hind paw. At 1 cm proximally to the nerve trifurcation, a tight ligature was created around 33-50% of the sciatic nerve using a 9-0 nonabsorbable virgin silk suture (Alcon â Surgical Inc., Fort Worth, TX, USA), leaving the rest of the nerve undamaged. The muscle was then stitched with 6-0 silk (Alcon â Surgical Inc.), and the incision was closed with wound clips. Shamoperated mice underwent the same surgical procedure except that the sciatic nerve was not ligated.
Catheterization
Mice were implanted with indwelling i.v. silastic catheter, as previously reported (Soria et al., 2005) .
Briefly, a 6-cm length of silastic tubing (0.3 mm inner diameter, 0.64 mm outer diameter) (Silastic â , Dow Corning Europe, Seneffe, Belgium) was fitted to a 22-gauge steel cannula (Semat Technical Ltd., Herts, UK) that was bent at a right angle and then embedded in a cement disc (Dentalon Plus, Heraeus Kulzer, Wehrheim, Germany) with an underlying nylon mesh. The catheter tubing was inserted 1.3 cm into the right jugular vein and anchored with suture. The remaining tubing ran subcutaneously to the cannula, which exited at the mid-scapular region. All incisions were sutured and coated with antibiotic ointment (Bactroban, GlaxoSmithKline, Madrid, Spain).
Nociception
Hypersensitivity to noxious thermal stimuli and punctate mechanical stimulation were used as outcome measures of the neuropathic pain model. The behavioural manifestations of neuropathic pain were evaluated the day before, 3 and 6 days after the PSNL, as well as after the last drug self-administration session on day 16. Hypersensitivity to heat was assessed by evaluating the hind paw withdrawal latency in response to radiant heat with the plantar test apparatus (Ugo Basile, Varese, Italy), as previously reported (Hargreaves et al., 1988) . Punctate mechanical sensitivity was quantified by measuring the hind paw withdrawal response to von Frey filament stimulation through the up-down paradigm, as previously reported (Chaplan et al., 1994) .
Depressive-like behaviour
Depressive-like behaviour was evaluated the day after the last drug self-administration session (day 17) using the tail suspension test (Steru et al., 1985) . Briefly, mice were suspended 50 cm above the floor by means of an adhesive tape, placed approximately 1 cm from the tip of the tail. Two min after being hanged, time of immobility was quantified for 4 min. Mice were considered immobile only when they hung passively and motionless.
Statistics
Time courses of active and inactive operant responding were analysed with a repeated measures ANOVA with 'session' (session 4-10) and 'nose-poke' (active, inactive) as within-subject factors, and 'dose' and 'surgery' as between-subject factors, followed by Fisher's least significant difference post hoc test (LSD) when appropriate. Areas under the curve (AUCs) of time-course curves and depressive-like behaviour were analysed using a two-way ANOVA (surgery and treatment) followed by Fisher's LSD. Nociceptive behaviour (Plantar, von Frey) of nerveinjured and sham-operated mice was analysed by a two-way repeated measures ANOVA (surgery and treatment), followed by Bonferroni post hoc test. IBM SPSS 19 (SPSS Inc., Chicago, IL, USA) and GraphPad (GraphPad Software, La Jolla, CA, USA) were used to analyse the data, and differences were considered statistically significant when the p value was below 0.05.
Results
Pregabalin self-administration in shamoperated and nerve-injured mice
Mice were first trained to self-administer food pellets in operant chambers to acquire an operant behaviour maintained by food. This step was necessary for mice to reach interest for the active sensor before the surgery as previously reported (Bura et al., 2013) . All groups of mice displayed similar operant responding for food, showing averages of 59 AE 2.5 active responses and 5 AE 0.5 inactive responses (Mean AE SEM) on the last day of the training ( Fig. 2A, shaded areas) . After food training, mice were sham-operated or subjected to the PSNL surgery, and 4 days later, jugular catheterization was conducted to allow operant drug self-administration (Fig. 1) . Three days after catheter implantation, sham and PSNL mice were placed back in their chambers and started the i.v. self-administration sessions (1 h/day, 10 days). In these sessions, the food reinforcer was substituted by saline, pregabalin 1.5 mg/kg/inf or pregabalin 3 mg/kg/inf. After the last self-medication session, all mice received a thiopental dose to check the patency of the catheter. This revealed 13, 10 and 10 mice preserving the catheter in sham groups receiving saline, pregabalin 1.5 and 3 mg/kg/inf, respectively, and 8, 6 and 13 mice in PSNL groups receiving the same drug treatments. Data from the first 3 days of drug self-administration were discarded to avoid the interference of food-maintained operant behaviour. Analysis of the last seven drug self-administration sessions using a repeated measures ANOVA followed by Fisher's LSD post hoc test revealed that mice receiving pregabalin at 3 mg/kg/inf showed higher active responding than mice receiving saline, either when the PSNL injury was inflicted ( Fig. 2A, sessions 4-5-6 ) or when the sham operation was conducted (Fig. 1A, session 7) .
Hence, on specific days, mice exposed to pregabalin 3 mg/kg/inf showed more active responding than mice exposed to saline ( Fig. 2A) . In addition, shamoperated mice receiving pregabalin 3 mg/kg/inf showed significantly less inactive nose-pokes compared to sham mice receiving saline (p < 0.05, Fig. 2 ), which suggests better discrimination for the drug in sham mice receiving the high dose. Interestingly, mice receiving pregabalin 1.5 mg/kg/inf exhibited higher active responding when were shamoperated than being nerve-injured (Fig. 1A, session  4) . Thus, both sham and PSNL-operated mice showed high active responding for pregabalin, albeit the difference vs. saline was more apparent in nerve-injured than in sham-operated mice ( Fig. 2A) .
Areas under the curve (AUCs) of drug self-administration curves for active responding were significantly higher in PSNL-injured mice exposed to pregabalin 3 mg/kg/inf than in PSNL mice exposed to saline (Fig. 2B) . Sham-operated mice showed the same tendency, although the differences did not reach statistical significance (Fig. 2B) . Interestingly, AUCs for inactive responding showed the opposite trend, with mice exposed to pregabalin 3 mg/kg/inf exhibiting less inactive responding than mice exposed to saline (Fig. 2B, N .S. differences). In agreement, the discrimination between active and inactive sensors was higher in PSNL-injured mice treated with either dose of pregabalin than in nerveinjured mice receiving saline, as shown by the AUCs of the discrimination indices [(Active À Inactive)/ (Active + Inactive)] for the self-administration sessions (Fig. 2C) . Sham-operated mice receiving pregabalin at the high dose showed a nonsignificant trend for better discrimination (Fig. 2C) . Hence, nerve injury markedly increased the ability to discriminate the effects of pregabalin.
The presence of a potential sedative effect of pregabalin could interfere with operant responding. Representation of the accumulated number of nosepokes (active + inactive) along the 60-min selfadministration sessions (Fig. 2D) showed similar levels of operant responding in saline-treated mice and mice treated with the different doses of pregabalin. This pattern of operant responding revealed the absence of sedative effects that could interfere operant responding at these doses of pregabalin.
Antinociceptive effects of pregabalin selfadministration
The antinociceptive effects of pregabalin self-administration were evaluated using the plantar and the von Frey tests. Nociceptive responses were evaluated before the PSNL/sham surgery (day 0), after the surgery before drug self-administration (days 3 and 6 after PSNL/Sham) and after the last pregabalin selfadministration session (day 16). Basal nociception (day 0) was similar in all groups of mice in the plantar and von Frey tests (Fig. 3A and B) .
Nerve injury consistently decreased withdrawal latency to heat stimulation in the ipsilateral paw on days 3, 6 and 16 (***p < 0.001 vs. sham-operated mice, two-way ANOVA followed by Bonferroni post hoc test for multiple comparisons, Fig. 3A) . Pregabalin self-administration at 1.5 and 3 mg/kg/infusion significantly decreased the thermal hypersensitivity observed on days 3 and 6, showing a significant reduction in heat sensitivity compared to PSNL mice treated with saline on day 16 (Fig. 3A , p < 0.05 1.5 mg/kg/infusion vs. saline and p < 0.01 for 3 mg/kg/infusion vs. saline, two-way ANOVA). Thermal latencies of contralateral paws of all mice and ipsilateral paws of sham-operated mice remained stable thorough the whole experiment (Fig. 3A) . Therefore, self-administration of pregabalin at 1.5 and 3 mg/kg/inf induced similar decreases in heat hypersensitivity associated with the nerve injury.
As expected, sciatic nerve injury also induced ipsilateral mechanical hypersensitivity (Fig. 3B) . PSNLoperated mice experienced sharp decreases in mechanical thresholds, significant on days 3, 6 and 16 after the surgery (Fig. 3B , ***p < 0.001 vs. shamoperated mice, two-way ANOVA). Pregabalin selfadministration had antinociceptive effect when administered at 3 mg/kg/inf, significantly reducing on day 16 the mechanical sensitivity observed on days 3 and 6 (Fig. 3B , p < 0.001 vs. nerveinjured mice receiving saline or ### p < 0.001 vs. pregabalin at 1.5 mg/kg, two-way RM ANOVA). Conversely, pregabalin at 1.5 mg/kg/inf was ineffective relieving mechanical hypersensitivity (Fig. 3B) . Mechanical thresholds of contralateral paws and ipsilateral paws of sham-operated mice appeared stable through the complete experiment (Fig. 3A) . Hence, the effect of pregabalin alleviating mechanical sensitivity was present when the drug was selfadministered at 3, but not at 1.5 mg/kg/inf.
Effects of pregabalin self-administration on emotional-like manifestations of the neuropathic pain model
The effects of pregabalin self-administration on depressive-like behaviour associated with the peripheral neuropathy were evaluated in the tail suspension test the day after discontinuation of the treatment. Nerve-injured mice treated with saline showed a significant increase in immobility time when compared to sham-operated mice treated with saline (Fig. 4 , **p < 0.01). Conversely, nerve-injured mice treated with pregabalin at 3 mg/kg/inf showed immobility times similar to sham mice treated with saline. This emotional impairment was significantly reversed by pregabalin (3 mg/kg/inf) when compared to the depressive-like phenotype expressed by nerve-injured mice treated with saline (Fig. 4 , *p < 0.05). Conversely, PSNL mice treated with pregabalin 1.5 mg/kg/inf still showed depressive-like behaviour associated with the nerve injury (Fig. 4 , p < 0.05 vs. sham mice treated with saline). Overall, pregabalin administered at 3 mg/kg/inf reversed depressive-like behaviour associated with the nerve injury.
Discussion
This work describes the attenuation of the nociceptive and emotional-like manifestations of a neuropathic pain model in mice receiving an operant pregabalin self-administration to alleviate the spontaneous symptoms of this chronic pain. The selfadministration paradigm showed that nerve-injured Figure 2 Reinforcing properties of pregabalin. (A) Time course of pregabalin self-administration in sham and partial sciatic nerve ligation (PSNL)-operated mice. Active (filled squares) and inactive nose-pokes (empty squares) are plotted for the last food training session (shaded areas) and for the last seven drug self-administration sessions (white areas). Sham-operated mice receiving pregabalin at 3 mg/kg/inf showed higher active responding (session 7) and lower inactive responding (session 2) than sham mice receiving saline. Similarly, PSNL-operated mice treated with pregabalin 3 mg/kg/inf showed higher active responding than PSNL mice receiving saline (sessions 4,5,6). On session 4, mice receiving pregabalin 1.5 mg/kg/inf showed higher active responding than PSNL mice receiving the same treatment. p < 0.05 Pregabalin vs. Saline; *p < 0.05 PSNL vs. Sham; RM ANOVA followed by Fisher's LSD test. (B) Areas under the curve (AUCs) of drug self-administration time-course series for active (left graph) and inactive responding (right graph). Overall active responding was significantly higher in PSNL-injured mice exposed to pregabalin than in PSNL mice exposed to saline (*p < 0.05, two-way ANOVA followed by Fisher's LSD test). (C) AUCs of Discrimination Indices for the time-course series. PSNL-injured mice treated with either those of pregabalin showed better discrimination indices than nerve-injured mice receiving saline ( p < 0.01, two-way ANOVA). (D) Cumulative number of nose-pokes for pregabalin during the last operant session (session 10). The pattern of operant responding for the 60-min sessions suggests the absence of motor impairment or sedative effects associated with the doses of pregabalin tested. mice exposed to a pregabalin treatment exhibited higher active responding and discrimination indices than injured mice receiving saline, suggesting that pregabalin is able to elicit a drug-taking behaviour associated with relief of spontaneous neuropathic pain. In agreement, a previous CPP/CPA study performed in rats with carrageenan-induced inflammation revealed that low doses of pregabalin (1 mg/kg) inhibited the aversion to chambers paired with the carrageenan treatment (Rutten et al., 2011) . Importantly, these pregabalin doses inhibiting place aversion did not modify the behaviour in subjects without pain. Although CPP/CPA and self-administration paradigms provide distinct information about reward and reinforcement (Bardo and Bevins, 2000; Wise, 2004) , both methods represent indirect approaches to estimate the presence of spontaneous pain relief in chronic pain models (Mogil and Crager, 2004) , suggesting that pregabalin has efficacy alleviating nonevoked spontaneous pain. In our study, mice without neuropathy also showed a significant self-administration of pregabalin at the high dose. Previous CPP studies investigating the presence of reward associated with pregabalin treatments failed to show such an effect after oral administration (Andrews et al., 2001) . In contrast, intraperitoneal administration of high doses of pregabalin (3.16 and 10 mg/kg) induced preference for the chambers paired with the drug (Table 1; Rutten et al., 2011) . In our operant experimental conditions, higher doses of pregabalin could not be evaluated due to the complexity of the experimental paradigm, since a Figure 3 Nociceptive manifestations before and after pregabalin self-administration. Time courses show withdrawal latency to heat stimulation in the plantar test (A) and mechanical thresholds to von Frey filaments (B). Measures are shown before PSNL/sham surgery (day 0), after surgery before drug self-administration (days 3 and 6), and after surgery and self-administration (day 16). Values of ipsilateral (left panels) and contralateral paws (right panels) are plotted for each experimental group. (A) Sensitivity to heat. Plantar test showed a persistent decrease in the withdrawal latency to heat stimulation in ipsilateral paws of all PSNL-operated mice (days 3, 6 and 16, filled shapes, **p < 0.01 or ***p < 0.001 vs. shamoperated mice, two-way ANOVA followed by Bonferroni post hoc test). After drug self-administration (day 16), PSNL mice treated with pregabalin at 1.5 or 3 mg/kg/inf showed partial recovery of withdrawal latencies ( p < 0.05 and p < 0.01 vs. nerve-injured mice receiving saline). (B) Mechanical sensitivity. Von Frey filaments revealed a sharp decrease in mechanical thresholds in all PSNL-operated mice (days 3, 6 and 16, filled shapes, ***p < 0.001 vs. sham-operated mice). After drug self-administration, PSNL mice treated with pregabalin at 3 mg/kg/inf showed partial recovery ( p < 0.001 vs. nerve-injured mice receiving saline or ### p < 0.001 vs. pregabalin at 1.5 mg/kg/inf).
possible nonspecific motor effect of such a high dose of pregabalin would certainly interfere with the performance of the operant responding. Our data also suggest that high doses of pregabalin could be reinforcing, independently of its pain-relieving effects. These reinforcing effects raise possible concerns about the potential abuse liability of pregabalin. Indeed, several clinical studies are reporting increasing cases of abuse liability mainly in cases of concomitant opioid treatments (Baird et al., 2014; H€ akkinen et al., 2014) . Pregabalin has also been reported to modify the reinforcing effects of other drugs of abuse. Different studies described reduction in cocaine or alcohol self-administration in rats and humans treated with pregabalin (Stopponi et al., 2012; de Guglielmo et al., 2013) . This reduced drug self-administration after pregabalin could be interpreted as a decrease in the dose needed to obtain the rewarding effects of the drug. Indeed, a percentage of abusers admit using gabapentinoids to potentiate the 'high' obtained from opioid drugs (Baird et al., 2014) . Our selfadministration experiments showed certain levels of active responding in saline-receiving mice. A participation of food craving on this active responding cannot be ruled out from our data, since food pellets were previously delivered by operating the same active sensor. However, the initial food operant training is mandatory on this experimental approach since mice will not primarily self-administer a drug to alleviate pain in these experimental conditions (Bura et al., 2013) , in agreement with a previous research group that has also used similar operant approaches (Gutierrez et al., 2011) . PSNL mice showed a tendency to decrease operant responding (Fig. 2B) . A general decrease in operant responding may be related to anhedonic effects or cognitive impairment induced by the neuropathic injury (La Porta et al., 2016) . Interestingly, these effects did not reduce operant responding in nerveinjured mice exposed to pregabalin. A partial reversal of thermal and mechanical hypersensitivity was shown after pregabalin selfadministration. This is in agreement with a number of publications assessing the antinociceptive effects of pregabalin in neuropathic pain models in rodents (Field et al., 1999 (Field et al., , 2006 Nozaki-Taguchi et al., 2001; Kremer et al., 2016; La Porta et al., 2016) . It has been suggested that pregabalin can activate the descending noradrenergic system to alleviate both mechanical and heat sensitivity associated with the nerve injury (Takeuchi et al., 2007) . In our study, inhibition of thermal sensitivity was found at high and low pregabalin doses (3 and 1.5 mg/kg/inf). Conversely, alleviation of mechanical hypersensitivity was only found after self-administration of the high pregabalin dose. Those differences are in line with other studies in mouse models of peripheral neuropathic pain suggesting distinct modulation of mechanical and thermal hypersensitivity after pregabalin administration (Takeuchi et al., 2007; Wang et al., 2015) . Thus, knockout mice for a2d receptors, the main site of action of pregabalin, showed increased neuropathic mechanosensitivity, whereas thermal hyperalgesia was unaffected (Patel et al., 2013) . In addition, pregabalin did not modify mechanical and thermal thresholds in sham-operated mice, as expected from previous studies showing unchanged nociceptive thresholds after different pregabalin treatments (Kremer et al., 2016; La Porta et al., 2016) .
Pregabalin self-administration at the high dose significantly decreased the emotional-like manifestations associated with neuropathic pain in nerveinjured mice. Pregabalin has shown preventive effect inhibiting depressive-like behaviour after chronic restraint stress in rodents (Valente et al., 2012) and demonstrates clinical efficacy reducing ratings of anxiety and depression (Montgomery et al., 2008; Stein et al., 2008) . Conversely, noncontingent Figure 4 Emotional-like manifestations of neuropathic pain after pregabalin self-administration. Times of immobility in the tail suspension test one day after termination of the operant drug self-administration. Partial sciatic nerve ligation (PSNL)-operated mice treated with saline showed a significant increase in immobility compared to sham-operated mice receiving saline (**p < 0.01, two-way ANOVA followed by Fisher's LSD test). PSNL-operated mice treated with pregabalin at 1.5 mg/kg/inf still showed increased depressive-like behaviour (*p < 0.05). Conversely, nerve-injured mice treated with pregabalin 3 mg/kg/inf did not show depressive-like behaviour ( p < 0.05 vs. PSNL mice treated with saline).
intraperitoneal administration of pregabalin did not modify the depressive-like manifestations induced by the complex Freund's adjuvant or the PSNL models of chronic pain (Maciel et al., 2013; La Porta et al., 2016 ). The present model of i.v. pregabalin selfadministration may be more efficient mimicking clinical outcomes, since the active mouse operant responding required to alleviate the pain manifestations could lead to different motivational responses that would influence the final effects of the treatment. A trend for increased tail suspension immobility was also observed in sham-operated mice receiving pregabalin at the high dose. It needs to be noted that depressive-like behaviour was evaluated the day after discontinuation of the treatment, and a paradoxical withdrawal response might have been elicited after the abrupt cessation of pregabalin treatment. Clinical treatments have a tapper phase in which pregabalin doses are gradually decreased, and normally report the absence of withdrawal signs after treatments for neuropathic pain or generalized anxiety disorder Pande et al., 2003; Rosenstock et al., 2004; Frampton and Foster, 2006; Owen, 2007) . This tapper schedule could not be applied in our mouse model. Further studies are required to clarify the emotional consequences of the withdrawal of a chronic pregabalin treatment.
Our results show that mice maintain a contingent pregabalin self-administration at a dose effective alleviating mechanical and thermal hypersensitivity. This dose of pregabalin inhibits the depressive-like manifestations associated with this model of chronic neuropathic pain and also shows reinforcing effects in mice not exposed to chronic pain. Conversely, a lower dose of pregabalin, able to reduce thermal hypernociception, but without effects on mechanical sensitivity or depressive-like behaviour, is insufficient to induce significant operant responding for the drug. These findings suggest that analgesic drug intake associated with pain relief depends not only on the alleviation of specific nociceptive responses, but also on the inhibition of a multiplicity of symptoms that constitute the complexity of neuropathic pain syndromes. The multifaceted experimental approach used in this study allows the simultaneous evaluation of spontaneous pain relief, emotional and safety consequences of pregabalin treatment. The characterization of all these complementary aspects required for evaluating the effectiveness and safety of an analgesic treatment provides an important translational value of these preclinical findings and underlines the need of using these new experimental models to improve the predictive value of the preclinical data.
